122 related articles for article (PubMed ID: 18386818)
41. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Nobeyama Y; Okochi-Takada E; Furuta J; Miyagi Y; Kikuchi K; Yamamoto A; Nakanishi Y; Nakagawa H; Ushijima T
Int J Cancer; 2007 Jul; 121(2):301-7. PubMed ID: 17372906
[TBL] [Abstract][Full Text] [Related]
42. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
43. Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma.
Ferguson B; Handoko HY; Mukhopadhyay P; Chitsazan A; Balmer L; Morahan G; Walker GJ
Elife; 2019 Jan; 8():. PubMed ID: 30681412
[TBL] [Abstract][Full Text] [Related]
44. Expression profiling of UVB response in melanocytes identifies a set of p53-target genes.
Yang G; Zhang G; Pittelkow MR; Ramoni M; Tsao H
J Invest Dermatol; 2006 Nov; 126(11):2490-506. PubMed ID: 16888633
[TBL] [Abstract][Full Text] [Related]
45. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
46. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
47. C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.
Alessandrini L; Parrozzani R; Bertorelle R; Valentini E; Candiotto C; Giacomelli L; Midena E; Blandamura S
Acta Ophthalmol; 2013 Dec; 91(8):e641-5. PubMed ID: 23742652
[TBL] [Abstract][Full Text] [Related]
48. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
Takata M; Murata H; Saida T
Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
[TBL] [Abstract][Full Text] [Related]
49. Chronically sun-damaged melanomas express low levels of nuclear glutathione-S-transferase-π: an epidemiological and clinicopathological study in Italy.
Campione E; Medda E; Paternò EJ; Diluvio L; Ricozzi I; Carboni I; Costanza G; Rossi P; Rapanotti C; Di Stefani A; Chimenti S; Bianchi L; Orlandi A
Acta Derm Venereol; 2015 Jan; 95(1):40-4. PubMed ID: 24535144
[TBL] [Abstract][Full Text] [Related]
50. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.
Arnold M; de Vries E; Whiteman DC; Jemal A; Bray F; Parkin DM; Soerjomataram I
Int J Cancer; 2018 Sep; 143(6):1305-1314. PubMed ID: 29659012
[TBL] [Abstract][Full Text] [Related]
51. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.
Wilmott JS; Johansson PA; Newell F; Waddell N; Ferguson P; Quek C; Patch AM; Nones K; Shang P; Pritchard AL; Kazakoff S; Holmes O; Leonard C; Wood S; Xu Q; Saw RPM; Spillane AJ; Stretch JR; Shannon KF; Kefford RF; Menzies AM; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Scolyer RA
Int J Cancer; 2019 Mar; 144(5):1049-1060. PubMed ID: 30178487
[TBL] [Abstract][Full Text] [Related]
52. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
53. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
54. ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.
Liao YH; Hsu SM; Huang PH
Cancer Res; 2007 Dec; 67(24):11547-56. PubMed ID: 18089783
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.
Steitz J; Büchs S; Tormo D; Ferrer A; Wenzel J; Huber C; Wölfel T; Barbacid M; Malumbres M; Tüting T
Int J Cancer; 2006 Jan; 118(2):373-80. PubMed ID: 16049960
[TBL] [Abstract][Full Text] [Related]
56. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.
Murakami A; Mori T; Sakai H; Murakami M; Yanai T; Hoshino Y; Maruo K
Vet Comp Oncol; 2011 Sep; 9(3):219-24. PubMed ID: 21848624
[TBL] [Abstract][Full Text] [Related]
57. The gene expression signatures of melanoma progression.
Haqq C; Nosrati M; Sudilovsky D; Crothers J; Khodabakhsh D; Pulliam BL; Federman S; Miller JR; Allen RE; Singer MI; Leong SP; Ljung BM; Sagebiel RW; Kashani-Sabet M
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6092-7. PubMed ID: 15833814
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
59. Infrared radiation does not enhance the frequency of ultraviolet radiation-induced skin tumors, but their growth behaviour in mice.
Jantschitsch C; Weichenthal M; Maeda A; Proksch E; Schwarz T; Schwarz A
Exp Dermatol; 2011 Apr; 20(4):346-50. PubMed ID: 21410765
[TBL] [Abstract][Full Text] [Related]
60. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
